Match List-I with List-II
| List-I | List-II |
|---|---|
| Terms | Applications |
| (A) RNA interference | (I) ADA deficiency |
| (B) Genetically engineered insulin | (II) α-1-antitrypsin |
| (C) Gene therapy | (III) Meloidegyne incognitia |
| (D) Biological product | (IV) Eli Lilly |
Choose the correct answer from the options given below.
Answer & explanation
Correct answer: option 4
The correct answer is Option (4) → (A)-(III), (B)-(IV), (C)-(I), (D)-(II)
(A) RNA interference — this matches (III) Meloidegyne incognitia. RNAi was used to protect tobacco from this root nematode, by silencing the nematode’s own mRNA.
(B) Genetically engineered insulin — this matches (IV) Eli Lilly. In 1983 this American company made the A and B chains of human insulin in E. coli.
(C) Gene therapy — this matches (I) ADA deficiency. The first clinical gene therapy (1990) treated a 4-year-old girl with adenosine deaminase deficiency.
(D) Biological product — this matches (II) α-1-antitrypsin. Transgenic animals produce this human protein, used to treat emphysema.